Schwann cell dedifferentiation-associated demyelination leads to exocytotic myelin clearance in inflammatory segmental demyelination

Glia. 2017 Nov;65(11):1848-1862. doi: 10.1002/glia.23200. Epub 2017 Aug 10.

Abstract

Schwann cells (SCs), which form the peripheral myelin sheath, have the unique ability to dedifferentiate and to destroy the myelin sheath under various demyelination conditions. During SC dedifferentiation-associated demyelination (SAD) in Wallerian degeneration (WD) after axonal injury, SCs exhibit myelin and junctional instability, down-regulation of myelin gene expression and autophagic myelin breakdown. However, in inflammatory demyelinating neuropathy (IDN), it is still unclear how SCs react and contribute to segmental demyelination before myelin scavengers, macrophages, are activated for phagocytotic myelin digestion. Here, we compared the initial SC demyelination mechanism of IDN to that of WD using microarray and histochemical analyses and found that SCs in IDN exhibited several typical characteristics of SAD, including actin-associated E-cadherin destruction, without obvious axonal degeneration. However, autophagolysosome activation in SAD did not appear to be involved in direct myelin lipid digestion by SCs but was required for the separation of SC body from destabilized myelin sheath in IDN. Thus, lysosome inhibition in SCs suppressed segmental demyelination by preventing the exocytotic myelin clearance of SCs. In addition, we found that myelin rejection, which might also require the separation of SC cytoplasm from destabilized myelin sheath, was delayed in SC-specific Atg7 knockout mice in WD, suggesting that autophagolysosome-dependent exocytotic myelin clearance by SCs in IDN and WD is a shared mechanism. Finally, autophagolysosome activation in SAD was mechanistically dissociated with the junctional destruction in both IDN and WD. Thus, our findings indicate that SAD could be a common myelin clearance mechanism of SCs in various demyelinating conditions.

Keywords: Atg7; E-cadherin; Wallerian degeneration; autophagy; lysosome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Autophagy-Related Protein 7 / genetics
  • Autophagy-Related Protein 7 / metabolism
  • Axotomy / adverse effects
  • Cell Dedifferentiation / physiology*
  • Chloroquine / therapeutic use
  • Demyelinating Diseases / drug therapy
  • Demyelinating Diseases / etiology
  • Disease Models, Animal
  • Down-Regulation / drug effects
  • Down-Regulation / genetics
  • Female
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Myelin Proteins / genetics
  • Myelin Proteins / metabolism
  • Nerve Tissue Proteins / metabolism
  • Neuritis, Autoimmune, Experimental / drug therapy
  • Neuritis, Autoimmune, Experimental / pathology*
  • Neuritis, Autoimmune, Experimental / physiopathology*
  • Rats
  • Rats, Inbred Lew
  • Receptors, Urokinase Plasminogen Activator / genetics
  • Receptors, Urokinase Plasminogen Activator / metabolism
  • Schwann Cells / metabolism
  • Schwann Cells / pathology*
  • Schwann Cells / ultrastructure
  • Sciatic Neuropathy / drug therapy
  • Sciatic Neuropathy / pathology*
  • Sciatic Neuropathy / physiopathology*

Substances

  • Atg7 protein, mouse
  • Myelin Proteins
  • Nerve Tissue Proteins
  • Plaur protein, mouse
  • Receptors, Urokinase Plasminogen Activator
  • Chloroquine
  • Autophagy-Related Protein 7